Financials data is unavailable for this security.
View more
Year on year Trinity Biotech PLC had revenues fall -9.10% from 62.52m to 56.83m, though the company grew net income from a loss of 41.01m to a smaller loss of 24.02m.
Gross margin | 34.28% |
---|---|
Net profit margin | -38.01% |
Operating margin | -26.20% |
Return on assets | -26.80% |
---|---|
Return on equity | -- |
Return on investment | -35.44% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Trinity Biotech PLC fell by 2.89m. However, Cash Flow from Investing totalled 24.76m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 11.56m for operations while cash used for financing totalled 16.04m.
Cash flow per share | -2.56 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -19.24 |
---|---|
Tangible book value per share | -46.58 |
More ▼
Balance sheet in USDView more
Current ratio | 1.78 |
---|---|
Quick ratio | 0.8936 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.46 |
More ▼